Dan Lynch

Dan joined GV in 2021 as Executive Venture Partner. Since 2007, Dan has advised and served as an executive chair or member of the boards for a number of biopharmaceutical companies including Stromedix (acquired by Biogen), Avila Therapeutics (acquired by Celgene Corporation), Nimbus Discovery, Edimer Pharmaceuticals, Ember Therapeutics, Proclara Biosciences, Surface Oncology, Sesen Bio (formerly Eleven Biotherapeutics), eGenesis Bio and BIND Biosciences.

Dan also served as entrepreneur in residence and venture partner at Third Rock Ventures and was a senior advisor at the firm until 2021.

He currently serves on the boards of Blueprint Medicines, bluebird bio, SpringWorks Therapeutics, Translate Bio (formerly RaNA Therapeutics), Xilio Therapeutics, and Alpha Omega SPAC.

Previously, Dan served as CEO and CFO of ImClone Systems Corporation. As CEO, he led the company through a significant turnaround, helping to restore its reputation and secure FDA approval of ERBITUX (Cetuximab), a novel cancer treatment. As CFO, Dan led negotiations to form a major partnership between ImClone and Bristol-Myers Squibb. Earlier in his career, he held several financial positions at Bristol-Myers Squibb for more than 15 years. For five years, he served on the board of directors and the audit committee at U.S. Oncology, Inc. until its acquisition by McKesson in 2010.

Dan received his B.A. in mathematics from Wesleyan University and his M.B.A. from the Darden Graduate School of Business Administration at the University of Virginia.